Improved insulin sensitivity by anti-TNFα antibody treatment in patients with rheumatic diseases
- 1Department of General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
- 2Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
- 3Department of General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
- 4Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands
- 5Department of General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
- Correspondence to:
Dr C Popa
Department of Rheumatology, Radboud University Nijmegen Medical Centre, P O Box 9101, Nijmegen 6500 HB, The Netherlands; c.popa{at}aig.umcn.nl
- Accepted 10 October 2006
Insulin resistance is a key factor in the pathogenesis of the metabolic syndrome and type 2 diabetes, but the underlying mechanisms remain poorly understood. Adipocytokines, including tumour necrosis factor α (TNFα), interleukin 6, leptin and adiponectin,1,2 are increasingly recognised as important regulators of both insulin sensitivity, as well as inflammation, and a dysregulation of their levels and/or functions has been shown in both obesity and rheumatoid arthritis.3 Further investigations have substantiated the important negative effects of TNFα on insulin-mediated glucose uptake and the development of insulin resistance.4 In this study, the influence of therapeutic TNFα blockade on insulin sensitivity was investigated in regularly treated patients with rheumatic diseases.
A group of eight patients who were non-diabetic and having various chronic inflammatory disorders (table 1) were investigated in an open prospective …








